FDA. FDA approves ensartinib for ALK-positive locally advanced or metastatic non-small cell lung cancer. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ensartinib-alk-positive-locally-advanc...
8. Haratake N, Seto T, Takamori S, et al. Short progression-free survival of ALK inhibitors sensitive to secondary mutations in ALK-positive NSCLC patients. Thorac Cancer. 2019;10(9):1779–1787. doi:10.1111/1759- 7714...
“The approval of [alectinib] marks a pivotal moment for [patients with] newly diagnosed with early-stage ALK-positive lung cancer, who until now, were not able to receive ALK-specific therapy,” said Ken Culver, director of Research and Clinical Affairs at ALK Positive, Inc. “These patient...
Anaplastic lymphoma kinase (ALK) is a potent oncogenic driver in lung cancer. ALK tyrosine kinase inhibitors yield significant benefit in patients with ALK fusion-positive (ALK+) lung cancers; yet the durability of response is limited by drug resistance.
ALK-positive patients treated with crizotinib had a one-year overall survival rate of 74% and a two-year overall survival rate of 54%. Median overall survival had not been reached. This compared with outcomes for the ALK-positive controls of one-year overall survival of 73% and tw...
Learn more ALECENSA FOR PEOPLE WITH ALK+ NSCLC that has spread to other parts of the body Learn more ALK+=positive for the biomarker called anaplastic lymphoma kinase; NSCLC=non-small cell lung cancer. Important Safety Information & Indications ...
rearrangements in NSCLC (Table 1).26,38,39,47–66 Relatively low sensitivities that had been reported by some studies were attributed in part to focally/ weakly ALK-positive tumors making determination of ALK status challenging; thus, the OptiView Amplification Kit (Ventana Medical Systems Inc.)...
ALK Announces Positive Interim Results from Its Phase I/II Clinical Trial Dec. 18 CI Alk-Abello A/S Approves in Europe for Treatment of Young Children Dec. 12 CI ALK-Abelló A/S, Q3 2024 Earnings Call, Nov 14, 2024 Nov. 14 ALK-Abelló A/S Reports Earnings Results for the Third...
Modern Pathology An Official Journal of the United States & Canadian Academy of Pathology IncValera A, Colomo L, Martinez A, et al. ALK-‐positive large B-‐cell lymphomas express a terminal B-‐cell differentiation program...
Pfizer’s Xalkori (crizotinib) Approved by FDA for ALK-positive Anaplastic Large Cell Lymphoma in Children and Young Adults NEW YORK--(BUSINESS WIRE) January 14, 2021 -- Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) appro...